AKLIEF

Peak

trifarotene

Galderma
NDATOPICALCREAM
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1

Mechanism of Action

(RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. The exact process by which trifarotene ameliorates acne is unknown.

Pharmacologic Class:

Retinoid

Clinical Trials (1)

NCT05550337Phase 3Completed

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

Started Sep 2022
807 enrolled
Acne Vulgaris

Loss of Exclusivity

LOE Date
May 30, 2033
88 months away
Patent Expiry
May 30, 2033

Patent Records (3)

Patent #ExpiryTypeUse Code
7807708
Jul 19, 2031
SubstanceProduct
—
9084778
May 30, 2033
Product
U-134
9498465
May 30, 2033
Product
U-1033
Company
Galderma
Galderma
TX - Dallas
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers